

Paul Schultzy

170020

Access DB#

# SEARCH REQUEST FORM

RECEIVED  
Scientific and Technical Information Center

OCT 31 2005

11/07/05

Requester's Full Name: Rebecca Examiner #: 69826 Date: 10/31/05  
Art Unit: 1614 Phone Number 30(S11C) Serial Number: 101628141  
Mail Box and Bldg/Room Location: 3 C70 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: \_\_\_\_\_

Inventors (please provide full names): All attached

Earliest Priority Filing Date: \_\_\_\_\_

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please provide structures for

a) milnacipran

b) sertraline

c) bupropion

d) venlafaxine

e) duloxetine

& search them

1. to treat depression

2. to " atypical depression 2° to pain (DSP)

- how is DSP defined & is is considered non-responsive to usual tx for depression (e.g. tricyclics)

Thank you

Rebecca

See item 1

- what other compounds are known to be dual norep. serot. reuptake inhib.  
are they known to tx depression / DSP + tripe reuptake inhib.

## STAFF USE ONLY

### Type of Search

### Vendors and cost where applicable

Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: _____	Litigation _____	Lexis/Nexis _____
Searcher Prep. Review Time _____	Fulltext _____	Sequence Systems _____
Clerical Prep. Time: _____	Patent Family _____	WWW/Internet _____
Online Time _____	Other _____	Other (specify) _____

# Application

Cook 10/628,141

11/07/2005

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:142815 HCAPLUS  
DOCUMENT NUMBER: 140:157480  
ENTRY DATE: Entered STN: 22 Feb 2004  
TITLE: Monoamine reuptake inhibitors for the treatment and  
prevention of depression secondary to pain  
INVENTOR(S): Rao, Srinivas G.; Kranzler, Jay D.  
PATENT ASSIGNEE(S): Cypress Bioscience, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S.  
Ser. No. 28,547.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
INT. PATENT CLASSIF.:  
MAIN: A61K031-165  
US PATENT CLASSIF.: 514619000  
CLASSIFICATION: 1-11 (Pharmacology)  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004034101	A1	20040219	US 2003-628141	20030724 <--
US 2003139476	A1	20030724	US 2001-14149	20011105
US 6635675	B2	20031021		
US 2003130353	A1	20030710	US 2001-28547	20011219
US 6602911	B2	20030805		
PRIORITY APPLN. INFO.:			US 2001-14149	A2 20011105
			US 2001-28547	A2 20011219
			US 2002-398676P	P 20020724
			US 2003-443035P	P 20030128

## PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004034101	ICM	A61K031-165
	INCL	514619000
US 2004034101	NCL	514/619.000
	ECLA	A61K031/00; A61K031/131+M; A61K031/135+M; A61K031/165; A61K031/165+M <--
US 2003139476	NCL	514/620.000
	ECLA	A61K031/00; A61K031/165
US 2003130353	NCL	514/620.000
	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M

## ABSTRACT:

Methods for the prevention or treatment of a typical depression secondary to pain (DSP) have been developed. The method generally involves administering an effective amount of a monoamine reuptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment, a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor (SNRI) compound of a specific type, or a pharmaceutically acceptable salt thereof, is administered. The most preferred SNRI compds. are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition. The most preferred compound is milnacipran, or a bioequivalent or pharmaceutically acceptable salt thereof. Other preferred compds. are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof. In yet another embodiment, a therapeutically effective amount of a non-tricyclic triple reuptake inhibitor (TRI) compound of a specific type, or a

pharmaceutically acceptable salt thereof, is administered. The TRI compds. are characterized by their ability to block the reuptake (and hence increase central concns. of) the three primary brain monoamines: serotonin, noradrenaline, and dopamine.

SUPPL. TERM: monoamine reuptake inhibitor depression secondary to pain;  
milnacipran duloxetine venlafaxine depression secondary to pain

INDEX TERM: Glutamate antagonists  
(NMDA antagonists; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Pain  
(abdominal; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Disease, animal  
(back pain, lower back; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Body, anatomical  
(back, disease, pain, lower back; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Pain  
(back, lower back; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Disease, animal  
(chronic pain from; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Pain  
(chronic; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Mental disorder  
(depression; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Head  
(face, myofascial face pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: 5-HT reuptake inhibitors  
Analgesics  
Antidepressants  
Drug delivery systems  
Headache  
Human  
Pain  
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Emotion  
(mood reactivity; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Nerve, disease  
(neuropathy, neuropathic pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Nervous system  
(neurovegetative symptoms; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Abdomen, disease  
Neck, anatomical

(pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Body, anatomical  
(pelvis, pelvic pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Biological transport  
(reuptake; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Seizures  
(risk; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: Thorax  
(typical chest pain; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: 50-67-9, Serotonin, biological studies  
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)  
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)


INDEX TERM: 765-30-0D, Aminocyclopropane, derivs. 92623-85-3, Milnacipran 106650-56-0, Sibutramine  
ROLE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

INDEX TERM: 51-41-2, Norepinephrine 51-61-6, Dopamine, biological studies  
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)  
(reuptake inhibitors; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

IT 50-67-9, Serotonin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

RN 50-67-9 HCAPLUS


CN 1H-Indol-5-ol, 3-(2-aminoethyl)- (9CI) (CA INDEX NAME)



IT 765-30-0D, Aminocyclopropane, derivs. 92623-85-3, Milnacipran 106650-56-0, Sibutramine  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

RN 765-30-0 HCAPLUS


CN Cyclopropanamine (9CI) (CA INDEX NAME)



RN 92623-85-3 HCAPLUS


CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-,  
(1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106650-56-0 HCAPLUS

CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl- $\alpha$ -(2-methylpropyl)- (9CI) (CA INDEX NAME)




IT 51-41-2, Norepinephrine 51-61-6, Dopamine, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(reuptake inhibitors; monoamine reuptake inhibitors for treatment and prevention of depression secondary to pain)

RN 51-41-2 HCAPLUS


CN 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 51-61-6 HCAPLUS

CN 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:532350 HCAPLUS  
 DOCUMENT NUMBER: 139:63355  
 ENTRY DATE: Entered STN: 11 Jul 2003  
 TITLE: Methods using a dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain  
 INVENTOR(S): Kranzler, Jay D.; Rao, Srinivas G.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 14,149.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 INT. PATENT CLASSIF.:  
     MAIN: A61K031-5513  
     SECONDARY: A61K031-496; A61K031-485; A61K031-55; A61K031-198; A61K031-165; A61K031-137  
 US PATENT CLASSIF.: 514620000; 514217000; 514221000; 514253040; 514282000; 514649000; 514561000; 514567000  
 CLASSIFICATION: 1-11 (Pharmacology)  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003130353	A1	20030710	US 2001-28547	20011219
US 6602911	B2	20030805		
US 2003139476	A1	20030724	US 2001-14149	20011105
US 6635675	B2	20031021		
WO 2003053426	A1	20030703	WO 2002-US40976	20021219
W: CA, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
US 2004019116	A1	20040129	US 2003-623431	20030718
US 2004229956	A1	20041118	US 2003-623378	20030718
US 2004034101	A1	20040219	US 2003-628141	20030724 <--
PRIORITY APPLN. INFO.:			US 2001-14149	A2 20011105
			US 2001-28547	A1 20011219
			US 2002-398676P	P 20020724
			US 2003-443035P	P 20030128

## PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003130353	ICM	A61K031-5513
	ICS	A61K031-496; A61K031-485; A61K031-55; A61K031-198; A61K031-165; A61K031-137
	INCL	514620000; 514217000; 514221000; 514253040; 514282000; 514649000; 514561000; 514567000
US 2003130353	NCL	514/620.000



US 2003139476	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
	NCL	514/620.000
WO 2003053426	ECLA	A61K031/00; A61K031/165
US 2004019116	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
	NCL	514/620.000
US 2004229956	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
	NCL	514/619.000
US 2004034101	ECLA	A61K031/00; A61K031/135+M; A61K031/165; A61K031/165+M
	NCL	514/619.000
	ECLA	A61K031/00; A61K031/131+M; A61K031/135+M; A61K031/165; A61K031/165+M

&lt;--

## ABSTRACT:

The invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin-norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein the dual serotonin-norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

SUPPL. TERM:	pain treatment dual serotonin norepinephrine reuptake inhibitor; fibromyalgia syndrome treatment dual serotonin norepinephrine reuptake inhibitor; chronic fatigue syndrome treatment dual serotonin norepinephrine reuptake inhibitor; milnacipran pain fibromyalgia chronic fatigue syndrome
INDEX TERM:	Fatigue, biological (chronic fatigue syndrome; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)
INDEX TERM:	5-HT reuptake inhibitors Analgesics Biological transport Human Pain (dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)
INDEX TERM:	Anticonvulsants Antidepressants Appetite depressants Hypnotics and Sedatives Muscle relaxants Nervous system stimulants (dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain, and use with other agents)
INDEX TERM:	Muscle, disease (fibromyalgia; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)
INDEX TERM:	Drug delivery systems (sustained-release; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)
INDEX TERM:	Drug delivery systems (unit doses; dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)


INDEX TERM: 50-67-9, Serotonin, biological studies  
 51-41-2, Norepinephrine  
 ROLE: BSU (Biological study, unclassified); BIOL (Biological study)  
 (dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: 92623-85-3, Milnacipran  
 ROLE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

INDEX TERM: 57-27-2, Morphine, biological studies  
 59-92-7, biological studies 76-57-3, Codeine 298-46-4, Carbamazepine 300-62-9, Amphetamine 439-14-5, Valium 4205-90-7, Clonidine 19794-93-5, Trazodone 27203-92-5, Tramadol 51322-75-9, Tizanidine 60142-96-3, Neurontin 104632-26-0, Pramipexole 106650-56-0, Sibutramine 148553-50-8, Pregabalin  
 ROLE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain, and use with other agents)


IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (dual serotonin-norepinephrine reuptake inhibitor for treating fibromyalgia syndrome, chronic fatigue syndrome, and pain)

RN 50-67-9 HCAPLUS  
 CN 1H-Indol-5-ol, 3-(2-aminoethyl)- (9CI) (CA INDEX NAME)



RN 51-41-2 HCAPLUS  
 CN 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 92623-85-3, Milnacipran




RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(dual serotonin-norepinephrine reuptake inhibitor for treating  
fibromyalgia syndrome, chronic fatigue syndrome, and pain)

RN 92623-85-3 HCAPLUS

CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-,  
(1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 57-27-2, Morphine, biological studies 59-92-7,  
biological studies 76-57-3, Codeine 298-46-4,  
Carbamazepine 300-62-9, Amphetamine 439-14-5, Valium  
4205-90-7, Clonidine 19794-93-5, Trazodone  
27203-92-5, Tramadol 51322-75-9, Tizanidine  
60142-96-3, Neurontin 104632-26-0, Pramipexole  
106650-56-0, Sibutramine 148553-50-8, Pregabalin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(dual serotonin-norepinephrine reuptake inhibitor for treating  
fibromyalgia syndrome, chronic fatigue syndrome, and pain, and use with  
other agents)

RN 57-27-2 HCAPLUS

CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-  
(5α,6α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 59-92-7 HCAPLUS


CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 76-57-3 HCAPLUS  
 CN Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-,  
 (5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 298-46-4 HCAPLUS  
 CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 300-62-9 HCAPLUS  
 CN Benzeneethanamine,  $\alpha$ -methyl- (9CI) (CA INDEX NAME)




RN 439-14-5 HCAPLUS  
 CN 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- (8CI,  
 9CI) (CA INDEX NAME)



RN 4205-90-7 HCAPLUS  
CN 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 19794-93-5 HCAPLUS  
CN 1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)




RN 27203-92-5 HCAPLUS  
CN Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 51322-75-9 HCAPLUS  
CN 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 60142-96-3 HCAPLUS


CN Cyclohexaneacetic acid, 1-(aminomethyl)- (9CI) (CA INDEX NAME)



RN 104632-26-0 HCAPLUS


CN 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 106650-56-0 HCAPLUS


CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 148553-50-8 HCAPLUS


CN Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 92623-85-3 REGISTRY  
ED Entered STN: 17 Dec 1984  
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-,  
(1R,2S)-rel- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-,  
cis-(±)-  
OTHER NAMES:  
CN (±)-Milnacipran  
CN (1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide  
CN Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-  
CN Midalcipran  
CN **Milnacipran**  
CN Toledomin  
FS STEREOSEARCH  
DR 105310-09-6  
MF C15 H22 N2 O  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS,  
BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, DDFU, DRUGU, EMBASE,  
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROMT,  
PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

248 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
249 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 106650-56-0 REGISTRY  
ED Entered STN: 14 Feb 1987  
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl- $\alpha$ -(2-methylpropyl)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Medaria  
CN Meridia  
CN **Sibutramine**  
FS 3D CONCORD  
MF C17 H26 Cl N  
CI COM  
SR World Health Organization (WHO)  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

455 REFERENCES IN FILE CA (1907 TO DATE)  
30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
456 REFERENCES IN FILE CAPLUS (1907 TO DATE)




L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 71195-57-8 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-, (±)-  
OTHER NAMES:  
CN **Bicifadine**  
DR 86215-52-3  
MF C12 H15 N  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA,  
CAPLUS, CASREACT, CBNB, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS,  
IMSPATENTS, IMSRESEARCH, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER,  
USAN, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10 REFERENCES IN FILE CA (1907 TO DATE)  
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 93413-69-5 REGISTRY  
ED Entered STN: 18 Dec 1984  
CN Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA  
INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, (±)-  
OTHER NAMES:  
CN (±)-Venlafaxine  
CN Venlafaxin  
CN **Venlafaxine**  
CN Venlafexine  
DR 131801-71-3  
MF C17 H27 N O2  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS,  
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN,  
DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*, IMSDRUGNEWS, IMSPATENTS,  
IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS,  
RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

940 REFERENCES IN FILE CA (1907 TO DATE)  
16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
946 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 116539-59-4 REGISTRY  
ED Entered STN: 25 Sep 1988  
CN 2-Thiophenepropanamine, N-methyl- $\gamma$ -(1-naphthalenyloxy)-, ( $\gamma$ S)-  
(9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 2-Thiophenepropanamine, N-methyl- $\gamma$ -(1-naphthalenyloxy)-, (S)-  
OTHER NAMES:  
CN (S)-Duloxetine  
CN **Duloxetine**  
CN LY 248686  
FS STEREOSEARCH  
MF C18 H19 N O S  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS,  
BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU,  
DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*,  
PATDPASPC, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2,  
USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

254 REFERENCES IN FILE CA (1907 TO DATE)  
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
257 REFERENCES IN FILE CAPLUS (1907 TO DATE)